![Mark Timney](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Timney
Amministratore Delegato presso
Attralus, Inc.
Profilo
Attualmente, Mark Timney è presidente di Blade Therapeutics, Inc. e amministratore delegato e direttore di The Medicines Co. Timney è anche nel consiglio di Biotechnology Innovation Organization, Pharmaceutical Research & Manufacturers of America e Sarissa Capital Acquisition Corp. Nella sua carriera passata il sig. Timney ha ricoperto la posizione di presidente e amministratore delegato di Purdue Pharma LP, presidente di Global Primary Care presso Merck & Co., Inc. e amministratore delegato e direttore di The Medicines Co. Mark Timney si è laureato presso l'Università di Northumbria.
Posizioni attive di Mark Timney
| Società | Posizione | Inizio |
|---|---|---|
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Direttore/Membro del Consiglio | - |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America BiotechnologyHealth Technology Provides pharmaceutical research and biotechnology services | Direttore/Membro del Consiglio | - |
Blade Therapeutics, Inc.
 Blade Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that focuses on developing treatments for fibrotic and neurodegenerative diseases | Presidente | 01/08/2020 |
Attralus, Inc.
 Attralus, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pan-amyloid removal therapeutics | Amministratore Delegato | 10/05/2021 |
Anfield Road LLC | Amministratore Delegato | 01/01/2017 |
Precedenti posizioni note di Mark Timney
| Società | Posizione | Fine |
|---|---|---|
| SARISSA CAPITAL ACQUISITION CORP. | Direttore/Membro del Consiglio | 13/04/2023 |
| THE MEDICINES COMPANY | Amministratore Delegato | 01/01/2020 |
Purdue Pharma LP
 Purdue Pharma LP Medical DistributorsDistribution Services Distributes medicines | Amministratore Delegato | 23/06/2017 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/07/2014 |
Formazione di Mark Timney
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
90
Relazioni di 1° grado
10
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 10 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for acute cardiovascular care | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
Purdue Pharma LP
Purdue Pharma LP Medical DistributorsDistribution Services Distributes medicines | Distribution Services |
University of Northumbria
 University of Northumbria Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America BiotechnologyHealth Technology Provides pharmaceutical research and biotechnology services | Health Technology |
Blade Therapeutics, Inc.
Blade Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that focuses on developing treatments for fibrotic and neurodegenerative diseases | Health Technology |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pan-amyloid removal therapeutics | Health Technology |
Sarissa Capital Acquisition Corp.
 Sarissa Capital Acquisition Corp. Financial ConglomeratesFinance Operates as blank check company | Finance |
Anfield Road LLC |
